Kangpu Presented Phase Ib Results of KPG-818 in SLE at ACR Convergence 2022

Shanghai, China, November 25, 2022 -- Kangpu Biopharmaceuticals, a clinical-stage company based in Shanghai, China, announced today that it has presented the Phase Ib results of KPG-818 in Systemic Lupus Erythematosus (SLE) at the 2022 American College of Rheumatology (ACR) Annual Meeting recently held in Philadelphia, Pennsylvania.

As the world’s largest and most anticipated academic gathering in the field of rheumatology, the ACR Annual Meeting provides an important platform for scholars and physicians from across the globe to obtain the latest information on cutting-edge research and clinical advances in this particular field. The results presented by Kangpu at the ACR Covergence 2022 are from the ongoing Phase Ib/IIa study of KPG-818 in patients with SLE.

Discovered by Kangpu Biopharmaceuticals, Ltd., KPG-818 is a novel CRL4-CRBN E3 ubiquitin ligase modulator with great CRBN binding affinity, which leads to rapid and effective degradation of Aiolos (IKZF3) and Ikaros (IKZF1), the transcription factors that play critical roles in B cell development and proliferation. KPG-818 also significantly inhibits levels of the inflammatory cytokines interleukin (IL)-6, tumor necrosis factor (TNF)-α and Interferon-alpha (IFN-α) in LPS stimulated hPBMC.

The Phase Ib part of the study was an open-label, multicenter, dose escalation, cohort study with a multiple ascending dose design. The primary objectives were to assess the safety and tolerability of multiple oral doses of KPG-818 in patients with SLE over a 14-day treatment period, and to characterize the multiple oral dose PK of KPG-818. Approximately 27 patients with SLE were enrolled in 4 cohorts at the proposed KPG-818 dose levels of 0.15, 0.6, 2, and 5 mg/day. Each cohort enrolled at least 6 patients to ensure at least 4 evaluable patients to allow adequate PK and safety profiling. KPG-818 was generally well-tolerated and most treatment-emergent adverse events (TEAEs) were grade 1 or 2. The PK data showed good dose-exposure correlation with steady state reached within 7 days. Treatment with KPG-818 resulted in robust and dose-dependent immune modulatory effects including degradation of Aiolos, B cell depletion, down-regulation of pDC, and up-regulation of Treg.

About Kangpu Biopharmaceuticals

Kangpu Biopharmaceuticals, Ltd. is a clinical-stage company focused on the discovery and development of innovative small molecules for the treatment of solid tumors, hematologic malignancies, autoimmune diseases, and inflammatory disorders through novel solutions including targeted protein ubiquitination and degradation. Kangpu has built a rich and solid pipeline of potential first-in-class and best-in-class drug candidates based on proprietary technologies, including NeoMIDES^TM, SelPDEiS^®, and X-SYNERGY^®, developed and patented worldwide by the Company.

For more information, please visit www.KangpuGroup.com.

Forward-Looking Statements

The statement(s) made in this press release describing Kangpu’s predictions, expectations, and objectives may be forward-looking statements within the meaning of applicable laws and regulations. These statements and expectations envisaged by the management are only estimates and actual results may differ materially from such expectations due to risks, uncertainties and other factors including, but not limited to, changes in regulatory and/or economic conditions, uncertain outcomes in these clinical studies, exposure to market risks, and other external and internal factors, which are beyond the control of Kangpu.